PAGE Therapeutics Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Series A
  • (Cancelled)

  • Latest Deal Amount
  • $50M

  • Investors
  • 4

PAGE Therapeutics General Information

Description

Operator of a platform-based oncology drug development company intended to discover and commercialize anti-metastatic compounds. The company works on the discovery, development, and commercialization of innovative compounds, enabling the oncology market to prevent the formation of new metastases in cancer patients with solid tumours.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Aeschenvorstadt 48
  • 4051 Basel
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Aeschenvorstadt 48
  • 4051 Basel
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PAGE Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 15-May-2023 $50M Cancelled Pre-Clinical Trials
2. Early Stage VC 17-Mar-2023 Completed Generating Revenue
1. University Spin-Out 01-Jan-2022 Completed Startup
To view PAGE Therapeutics’s complete valuation and funding history, request access »

PAGE Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series S Preference
To view PAGE Therapeutics’s complete cap table history, request access »

PAGE Therapeutics Patents

PAGE Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026119971-A1 Bufadienolide compounds substituted by a nitrogen heterocycle Pending 03-Dec-2024
WO-2026119973-A1 Novel compounds Pending 03-Dec-2024

PAGE Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PAGE Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Claris Ventures Venture Capital Minority
Kizoo Technology Capital Venture Capital Minority
XGEN Venture Impact Investing Minority
ETH Zurich University
To view PAGE Therapeutics’s complete investors history, request access »

PAGE Therapeutics FAQs

  • When was PAGE Therapeutics founded?

    PAGE Therapeutics was founded in 2022.

  • Where is PAGE Therapeutics headquartered?

    PAGE Therapeutics is headquartered in Basel, Switzerland.

  • What is the size of PAGE Therapeutics?

    PAGE Therapeutics has 6 total employees.

  • What industry is PAGE Therapeutics in?

    PAGE Therapeutics’s primary industry is Drug Discovery.

  • Is PAGE Therapeutics a private or public company?

    PAGE Therapeutics is a Private company.

  • What is PAGE Therapeutics’s current revenue?

    The current revenue for PAGE Therapeutics is .

  • How much funding has PAGE Therapeutics raised over time?

    PAGE Therapeutics has raised $4.29M.

  • Who are PAGE Therapeutics’s investors?

    Claris Ventures, Kizoo Technology Capital, XGEN Venture, and ETH Zurich have invested in PAGE Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process